Espervita
3 known investors
Espervita Therapeutics is a drug discovery company developing metabolic reprogramming therapies, with a lead compound (EVT0185) that inhibits acetyl-CoA metabolic enzymes to treat conditions such as MASH, chronic kidney disease, and liver and kidney fibrosis. It focuses on first-in-class small-molecule therapies for metabolic-dysfunction diseases.
Biotech
Investors · 3
Frequently asked questions
- What does Espervita do?
- Espervita Therapeutics is a drug discovery company developing metabolic reprogramming therapies, with a lead compound (EVT0185) that inhibits acetyl-CoA metabolic enzymes to treat conditions such as MASH, chronic kidney disease, and liver and kidney fibrosis. It focuses on first-in-class small-molecule therapies for metabolic-dysfunction diseases.
- Who are Espervita's investors?
- Espervita's investors include ID Ventures, Michigan Rise, WMU Biosciences Research & Commercialization Center.